

PostScript

LETTERS

If you have a burning desire to respond to a paper published in *Gut*, why not make use of our "rapid response" option?

Log onto our website (www.gutjnl.com), find the paper that interests you, and send your response via email by clicking on the "eletters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eletters" on our homepage.

The editors will decide as before whether to also publish it in a future paper issue.

TPMT in the treatment of inflammatory bowel disease with azathioprine

We read with interest the recent article by Lennard on the role of thiopurine methyltransferase (TPMT) enzyme in predicting azathioprine related toxicity in patients with inflammatory bowel disease (IBD) (*Gut* 2002;51:143-6). He concludes that measurement of TPMT activity has no specific role in identifying the risk of significant bone marrow toxicity in long term users of azathioprine. This conclusion is in agreement with other published work and emphasises the importance of ongoing haematological monitoring in IBD patients receiving this drug.¹ The importance of haematological monitoring in the early detection and prevention of azathioprine related toxicity is well recognised.² However, the duration of early monitoring is a matter of controversy. The current *British National Formulary* guidelines recommend that patients undergo blood tests on at least a weekly basis for the initial four weeks of therapy. The drug's manufacturers recommend a more stringent monitoring policy and in their view, initial monitoring should continue for the first eight weeks of




Figure 1 Time of occurrence for various toxicities during azathioprine therapy. *Onset of toxicity relates to time (in months) from the start of azathioprine treatment to the appearance/detection of toxicity. SE, side effects.

treatment. The American College of Gastroenterology guidelines recommend a slightly different approach, with fortnightly blood counts for the initial three months of therapy.³ The key issue in determining the value of these different approaches to monitoring is the time of onset of potentially life threatening bone marrow suppression following initiation of azathioprine treatment. These data are not available for patients with IBD.

In a retrospective study, we analysed the time of onset of all drug related toxicity in IBD patients post initiation of azathioprine therapy. A total of 110 consecutive IBD patients with a history of azathioprine use were identified (table 1). Patients were identified from the hospital inpatient enquiry system, IBD clinic, and pharmacy records. Mean azathioprine dose was 2 mg/kg/day (range 1-3). Mean age of the patients on azathioprine was 38.11 years (18-76). Seventeen of 110 patients (15%) suffered from azathioprine related early toxicity (table 1). Mean azathioprine dose in those showing drug toxicity was 100 mg/day (50-150). Most (77%) drug related toxic events manifested within the first 12 weeks of therapy (fig 1). However, the mean time of onset of drug related toxicity depended on the side effect observed. For example, most drug related nausea was observed within two weeks of commencing treatment while all cases of deranged liver function tests were detected within eight weeks of treatment onset. Significantly, this

was not true for bone marrow suppression. The mean duration of treatment in the two patients who experienced this side effect was 11 weeks (range 10-12). Both cases occurred outside the "stringent" eight week monitoring period recommended by the drug's manufacturer. Hence identification of bone marrow suppression would have been delayed using the current British and manufacturer's guidelines. Three further episodes of neutropenia were identified during long term (>3 months) treatment in three patients who continued on maintenance azathioprine (mean duration 101 weeks/patient, range 2 weeks to 5 years). In our practice, we feel that significant toxicity during the early (<3 months) period of therapy could have been missed by strictly following existing guidelines.

Early detection of abnormalities in asymptomatic patients helped in dose adjustment with resolution of side effects. In addition, early detection of azathioprine related bone marrow suppression is likely to save lives. We recommend that gastroenterologists employ an extended (three month) period of intensive haematological monitoring after initiation of azathioprine therapy in IBD. Although neutropenia is occasionally observed beyond this point, intensive monitoring for the duration of treatment, which may continue for years, is clearly not practical from a patient or service perspective. However, this serves to emphasise the importance of continuous patient education concerning "alarm symptoms" throughout the duration of azathioprine therapy.

A Qasim, J Seery, M Buckley, C O Morain

Gastroenterology Department, AMNCH, Tallaght, Dublin 24, Ireland

Correspondence to: A Qasim; qasim@tcd.ie

References

- Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. *Aliment Pharmacol Ther* 2002;16:389-98.
- Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. *Gut* 1993;34:1081-5.
- Hanauer SB, Sandborn W and The Practice Parameter Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. *Am J Gastroenterol* 2001;96:635-43.

Author's reply

Measurement of thiopurine methyltransferase (TPMT) status, prior to the start of azathioprine therapy, has a role in identifying the TPMT deficient patient at risk of severe myelosuppression and TPMT heterozygous individuals who are prone to early myelosuppression.^{1,2} The risk of azathioprine toxicity is well recognised but, as the authors state, the duration of early monitoring is a matter of controversy. The matter for debate is the time of onset of potentially life threatening myelosuppression.

Table 1 Patient characteristics and side effects encountered during the initial period of therapy (three months) with azathioprine in patients with inflammatory bowel disease

	Ulcerative colitis	Crohn's disease	Indeterminate	Total
Male	17	25	3	45
Female	15	48	2	65
Nausea/vomiting	1	5	0	6
Abnormal LFTs	3	1	0	4
Neutropenia	1	1	0	2
Thrombocytopenia	0	1	0	1
Infections	Herpes rash (1)	0	0	1
Pancreatitis	0	1	0	1
Miscellaneous associated symptoms	Tiredness (1)	Headache (1), allergic skin rash (1)	0	3

LFT, liver function test.

Quasim *et al* state that this information is not available for patients with inflammatory bowel disease (IBD). However, data can be derived from observations in other patients groups which may serve as useful guidelines for this time interval.

Reports of azathioprine induced severe myelosuppression in the TPMT deficient patient indicate that bone marrow toxicity is recorded after 3–10 weeks (median 4) of azathioprine therapy.^{1,3,4} In these reports the drug dosage varied from 1 to 2.9 mg/kg (median 1.7). One patient taking azathioprine at a dosage of 1 mg/kg developed myelosuppression (white blood cell count (WBC) $1.6 \times 10^9/L$, platelets $25 \times 10^9/L$) at 10 weeks¹ while another dosed at 1 mg/kg developed myelosuppression (WBC $3.8 \times 10^9/L$, platelets $80 \times 10^9/L$) by seven weeks.⁴ For the patient with an intermediate TPMT activity (heterozygotes with one variant and one wild-type allele), Black and colleagues² reported leucopenia (leucocyte counts 0.9 – $2.9 \times 10^9/L$) within one month of starting azathioprine (2–3 mg/kg) as second line therapy for rheumatic disease.

Specifically for the patient with Crohn's disease, Colombel and colleagues³ have reported that TPMT deficient individuals experience leucopenia or thrombocytopenia within 1.5 months of azathioprine therapy (100–150 mg/day) and that TPMT heterozygotes developed toxicity after 1–18 months (median 4) of therapy. Similar observations have been made by Schwab and colleagues⁶ who reported myelosuppression in a TPMT deficient Crohn's patient after 1.75 months of azathioprine at 1.5 mg/kg and in two TPMT heterozygous patients after 2.5 and 3 months of therapy at dosages of 1.0 and 1.5 mg/kg, respectively. The additional observation that those individuals with wild-type alleles ("normal" TPMT activity) can experience myelosuppression after weeks or years of azathioprine therapy^{5,6} illustrates the multifactorial nature of myelosuppression in this patient group and supports the need for continued vigilance with respect to blood count monitoring. The drug manufacturer's guidelines, as stated in the Association of the British Pharmaceutical Industry (ABPI) medicines compendium,⁷ advise that at a minimum, complete blood counts should be monitored weekly during the first eight weeks of therapy. The guidelines then continue, "this frequency may be reduced during later therapy to monthly intervals, or at least at intervals no longer than three months".

The data presented in the reports above indicate, particularly for the patient on low dose azathioprine in whom TPMT status is unknown, close adherence to the ABPI guidelines and continuation of, at a minimum, weekly full blood counts during the first three months of treatment. Because severe bone marrow toxicity can be precipitated by the addition of aminosallylate derivatives⁸ to the azathioprine regimen, the drug manufacturer's more stringent blood count monitoring scheme should be considered following such adjustments in the combination therapy of refractory IBD.

L Lennard

University of Sheffield, School of Medicine,
Academic Unit of Molecular and Clinical
Pharmacology, Floor L, Royal Hallamshire Hospital,
Glossop Rd, Sheffield S10 2JF, UK;
L.Lennard@sheffield.ac.uk

References

- 1 Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine

- toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. *Clin Pharmacol Ther* 1989;**46**:149–54.
- 2 Black AJ, McLeod H, Capell HA, *et al*. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. *Ann Intern Med* 1998;**129**:716–18.
- 3 Anstey A, Lennard L, Mayou SC, *et al*. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. *J Royal Soc Med* 1992;**85**:752–6
- 4 Ari ZB, Mehta A, Lennard L, *et al*. Azathioprine induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. *J Hepatol* 1995;**23**:351–4
- 5 Colombel J-F, Ferrari N, Debuysere H, *et al*. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. *Gastroenterology* 2000;**118**:1025–30
- 6 Schwab M, Schaffeler E, Marx C, *et al*. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. *Pharmacogenetics* 2002;**12**:429–36.
- 7 Association of the British Pharmaceutical Industry Medicines Compendium. <http://emc.vhn.net>
- 8 Lewis LD, Benin A, Szumlanski CL, *et al*. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. *Clin Pharmacol Ther* 1997;**62**:464–75.

Appendectomy and ulcerative colitis

Cosnes *et al* demonstrated that previous appendectomy is not only associated with a lower incidence of ulcerative colitis, but also with a less severe course of the disease. Although we can fully agree with this result, we disagree with the recommendation that "Patients genetically at high risk of developing ulcerative colitis may be considered as candidates for appendectomy with the objectives of preventing the development of ulcerative colitis and also decreasing its severity" (*Gut* 2002;**51**:803–7).

All previous studies, as well as the present study, have demonstrated an association only between previous appendectomy and ulcerative colitis. It has not been shown that performing appendectomy in healthy persons at increased risk of developing ulcerative colitis is beneficial. The association may as well have been caused by an unknown confounding factor, both leading to an increased risk of appendicitis and a decreased risk of developing (severe) ulcerative colitis. To illustrate this point is the following theoretical example: an epidemiological study on cardiovascular morbidity finds that the risk of cardiovascular events is inversely related to the risk of developing upper gastrointestinal haemorrhage. This could be due to the factor "treatment with aspirin" that could well explain the increased bleeding risk and the lower incidence of cardiovascular events. The confounding factor is the use of aspirin. It would be wrong to conclude that in patients without a history of bleeding, attempts should be undertaken to induce upper gastrointestinal bleeding in order to prevent cardiovascular morbidity.

Another argument against performing this surgical procedure in healthy persons is the finding that appendectomy in the absence of an inflamed appendix was not associated with

a decreased risk of ulcerative colitis, suggesting that appendicitis rather than appendectomy protects against ulcerative colitis.¹ Cosnes *et al* state that these results may not be correct as they included all patients with previous appendectomy and still found a less severe course. We believe they are incorrectly assuming this, as another possible explanation is that the effect of appendicitis is actually higher than the effect of appendectomy reported in the present study, which could have been diluted by inclusion of patients without appendicitis.

In conclusion, we believe that at present healthy persons at risk of developing ulcerative colitis should not be considered candidates for appendectomy outside clinical trials as evidence showing that appendectomy will protect these persons is lacking.

P C J ter Borg, H R van Buuren
Erasmus MC, Rotterdam, the Netherlands

Correspondence to: Dr P C J ter Borg, Dr
Molewaterplein 40, Rotterdam, the Netherlands;
pterborg@zonnet.nl

Reference

- 1 Andersson RE, Olaison G, Tysk C, *et al*. Appendectomy and protection against ulcerative colitis. *N Engl J Med* 2001;**344**:808–14.

Authors' reply

Many French surgeons in 1900 did recommend removing preventively all appendices of young people (see Marcel Proust, "A l'ombre des jeunes filles en fleur"). That was not our purpose. Indeed, the sentence pointed out by ter Borg and van Buuren in our paper did not give a recommendation but only made a suggestion to consider for appendectomy patients genetically at high risk of developing ulcerative colitis.

Ter Borg and van Buuren speculate that appendectomy and a benign course of ulcerative colitis may be linked through a confounding factor but they do not document their hypothesis. In fact, there is a large body of evidence supporting a causal relationship between appendectomy and no (or benign) ulcerative colitis, and the strongest demonstration of this relationship is the protective effect of early appendectomy in the T cell receptor α (TCR- α) knockout mouse model.¹ Note also that the Swedish study² which found that only appendectomy for inflammatory conditions protects against ulcerative colitis did not take into account cases of mild ulcerative colitis, a subgroup in which appendectomised patients may be over represented.

Finally, we do not believe that the effect of appendectomy on the course of ulcerative colitis is so high that it would remain after excluding all patients without appendicitis, thus probably two thirds of our patients.³ A key point however, like in the TCR- α knockout mouse model, is the date of appendectomy. Appendectomy protects against severe ulcerative colitis only when performed at a young age,² and before disease onset.^{4,5} This latter observation argues against any therapeutic effect of appendectomy after onset of ulcerative colitis. The problem is different when considering patients at risk for the disease.

We do believe that in a few years it will be possible to screen out young patients with a

predisposing genotype for ulcerative colitis, and a clinical trial assessing the benefits of prophylactic appendicectomy will be warranted.

J Cosnes, F Carbonnel, L Beaugerie, J-P Gendre

Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, Paris, France

Correspondence to: Professor J Cosnes, Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75571 Paris cedex 12, France; jacques.cosnes@sat.ap-hop-paris.fr

References

- 1 Mizoguchi A, Mizoguchi E, Chiba C, *et al*. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. *J Exp Med* 1996;**184**:707–15.
- 2 Andersson RE, Olaison G, Tysk C, *et al*. Appendectomy and protection against ulcerative colitis. *N Engl J Med* 2001;**344**:808–14.
- 3 Turet L, Rotman N, Hatton F, *et al*. La chirurgie digestive en France. Une étude épidémiologique nationale (1978–1982). *Gastroenterol Clin Biol* 1988;**12**:354–60.
- 4 Cosnes J, Carbonnel F, Beaugerie L, *et al*. L'appendicectomie préalable, mais non secondaire, améliore l'évolution de la rectocolite hémorragique. *Gastroenterol Clin Biol* 2002;**26**:A32.
- 5 Selby WS, Griffin S, Abraham N, Solomon MJ. Appendectomy protects against the development of ulcerative colitis but does not affect its course. *Am J Gastroenterol* 2002;**97**:2834–8.

Screening and surveillance for asymptomatic colorectal cancer in IBD

We would like to voice our concerns about some of the recommendations in the guidelines recently published by the British Society of Gastroenterology and Association of Coloproctology for screening and surveillance for asymptomatic colorectal cancer in patients with inflammatory bowel disease (*Gut* 2002;**51** (suppl V):v10–12).

(1) In the present medicolegal environment, failure to comply with guidelines which carry the imprimatur of respected national bodies will require vigorous defence should mishap occur. We do not believe the evidence is strong enough to justify the recommendation that every patient with extensive colitis of duration greater than 8–10 years should undergo regular colonoscopy. Firstly, it must be determined at each hospital whether it is possible and considered sufficiently cost effective to offer such a service within the constraint of local resources available. Secondly, if regular colonoscopy can be offered, then each patient should decide whether or not to accept regular colonoscopy after full discussion of its possible advantages and limitations.

(2) The success of colonoscopic surveillance programmes is disputed. Although some centres (including our own) have been protagonists for this approach, others have argued that it is not only labour intensive but also ineffective. Before imposing global national guidelines we should have firm evidence of a scheme's efficacy or, failing this, we should have multicentre consensus. The guidelines, as published, appear to be the sincerely held opinions of a single consultant team based on their own research and assessment of the literature, followed by approval of a committee,

but no indication is given of widespread consultation.

(3) The recommendations for patients with extensive colitis of a colonoscopy every third year during the second decade of disease, every second year during the third decade, and annual colonoscopies thereafter are complex. The evidence for an increasing risk of cancer in the second, third, and succeeding decades of disease duration is controversial, and is not borne out by the unstratified figures for patients with total colitis based on 26 reported studies in the meta-analysis reported by the authors of the guidelines, although an increase was observed in stratified data'. The strategy suggested therefore is not based on firm data, and in particular published data after the third decade are few due to the small numbers involved.

(4) We have concerns about the benefits during routine colonoscopic examinations of taking two to four random biopsy specimens every 10 cm. This approach is time consuming for both the colonoscopist and the pathology department, and adds a considerable financial burden to the programme (which is not included in Eaden and Mayberry's cost analysis). In theory, the risk of a false negative examination is reduced as more biopsies are taken but in practice the additional yield is very low indeed. During a recent study at St Mark's Hospital, almost 3000 random surveillance biopsies from such patients yielded no dysplasia (unpublished data).

(5) Considering the disputed efficacy of current colonoscopic surveillance programmes for patients with extensive ulcerative colitis, it is inappropriate at present to extend this by default to patients with left sided colitis or (by implication) those with Crohn's disease.

A Forbes, S Gabe, J E Lennard-Jones, K Wilkinson

St Mark's Hospital and Academic Institute, Watford Road, Harrow HA1 3UJ, UK

Correspondence to: Dr A Forbes; alastair.forbes@ic.ac.uk

Reference

- 1 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;**48**:526–35.

Authors' reply

We would like to thank Dr Forbes *et al* for their response to the guidelines published by the British Society of Gastroenterology (BSG) and the Association of Coloproctology of Great Britain and Ireland on screening and surveillance for asymptomatic colorectal cancer in patients with inflammatory bowel disease (*Gut* 2002;**51** (suppl V):v10–12). They raise a number of points which will be answered in turn.

(1) There are medicolegal implications of failing to comply with recommendations from a respected body but a guideline is precisely that—a guideline. They are not etched in stone and may need to be amended at future dates to continue to reflect best practice. The case of *Wilsher v Essex Area Health Authority*¹ demonstrates that all clinicians now need to practice to the highest standards. However, the courts (*Early v Newham Health Authority*) will consider local guidelines.² This will be of particular consequence to units that are unable to deliver standards that have been identified nationally, provided the local practice has been formulated into a local guide-

line. There is a wealth of data supporting the increased cancer risk in patients with ulcerative colitis and although evidence of the effectiveness of surveillance as practised in many centres is uncertain, such an approach is widespread. The purpose of guidelines is to identify good practice and to achieve a uniform approach throughout the country. The alternatives are to abandon surveillance or to offer haphazard and unstructured (and so ineffective) service. The anticipated cost of surveillance for both colitics and Crohn's patients is estimated to be £9600 per annum. Hopefully, all centres will be able to meet this cost but we realise funds may not be available initially which is one of the reasons for suggesting the guidelines are audited in five years. It is clearly stated in the guidelines that a discussion should take place between the doctor and patient informing them of their individual risk so that the patient can make an informed decision before embarking on a surveillance programme. Gone are the days of a paternalistic attitude, as patients should now accept some responsibility for their illness.³

(2) Forbes *et al* raise the point that before any guidelines are imposed there should be firm evidence of a scheme's efficacy. There are no randomised studies comparing different surveillance protocols or for that matter even surveillance versus no surveillance. As Forbes *et al* are well aware, it will never be possible to provide grade A recommendations on this issue and the best we can do is to assess surveillance programmes retrospectively. Data are accumulating that surveillance participants have reduced morbidity and mortality, as outlined in the guidelines, and one of the signatories to your letter has stated that surveillance improves survival.⁴ One notable review of surveillance programmes from the Leeds group did not show any benefit from surveillance but the group had very stringent criteria.⁵ They felt inclusion of dysplasia alone as a measure of success was of debatable value. Therefore, they limited their audit to those eventually found to have cancer. They also decided to exclude patients in whom cancer was found at an *initial* colonoscopy undertaken at least 12 years after the onset of symptoms. We feel that finding dysplasia is the very aim of surveillance and just because it is found on the first colonoscopy in a surveillance programme it should not be deemed a failure of surveillance.

As much consultation as possible was obtained before the guidelines were published. A national audit of the surveillance practices of gastroenterologists in the UK was conducted which revealed that although 94% of gastroenterologists performed surveillance, there was wide variation in practice.⁶ This alone suggests there would be little chance of a consensus opinion across the UK. Once the guidelines had been formulated, the Clinical Services and Standards Committee comprising approximately 40 individuals reviewed them. They then went through the usual guidelines process after being seen by the Clinical Services Committee and were examined by the IBD section of the BSG. After this they were posted on the BSG website for six weeks to attract comments from other members of the society. The guidelines then went back to the Clinical Services Committee after amendments were made on the basis of comments from the wide range of consultees. Finally, the guidelines were passed to the Executive Committee of the BSG for a further review and signing off. Thus the guidelines were fully evaluated before they were accepted and published. They are not simply the opinions of two consultant gastroenterologists.

(3) We appreciate that increasing the colonoscopy frequency with increasing duration of disease is more complicated than 1–2 yearly surveillance. However, we are sure that it is not too difficult to calculate and it actually reduces the number of colonoscopies being performed initially, so this must be regarded as a substantial improvement on the present routine practice of some gastroenterologists.

The meta-analysis *does* show an increasing cancer risk in the second and third decades of disease and is not controversial in the least.⁷ The whole point of stratified data was to see if the cancer incidence did increase by decade of disease. It is only stratified data that can be used in this way. Such data will give the most accurate estimate as it is only these data that included studies which reported cancer incidence stratified by decade and duration of patient follow up (19 studies). The decade specific incidence rates correspond to a cumulative risk of 1.6% (95% confidence interval (CI) 1.2–2%) by 10 years, 8.3% (95% CI 4.8–11.7%) by 20 years, and 18.4% (95% CI 15.3–21.5%) by 30 years.

The 26 studies Forbes *et al* refer to also included studies which reported cancer incidence where only duration of patient follow up was reported—that is, the incidence rates were not broken down for each decade. Even when these unstratified data were examined the cancer incidence still increased by decade of disease! The unstratified cumulative probabilities give a risk of 4.4% (95% CI 2.0–6.8%) at 10 years, 8.6% (95% CI 4.0–13.3%) at 20 years, and 12.7% (95% CI 6.0–19.3%) at 30 years.

Therefore, the strategy suggested is based on firm data. Of course the numbers of patients by the third decade are few but this is the nature of the beast. The use of a meta-analysis of cancer risk in ulcerative colitis overcomes the inadequacies of any reliance on smaller studies from single specialist centres.

(4) We accept that the cost of biopsies was not included in the cost analysis. There are numerous articles debating the number of biopsies which should be taken during a surveillance colonoscopy. Yes it is time consuming but we all know that to stand any chance of detecting dysplasia, the more biopsies taken the better. What is the point in surveillance at all if it is not conducted to the best standard? It would be interesting to know from the unpublished St Mark's data how many biopsies were taken per colonoscopy. If for example only 10 biopsies were being taken at each examination, we would expect the chance of detecting dysplasia to be low.

(5) As patients with Crohn's colitis have been shown to have the same cancer risk as patients with extensive ulcerative colitis, it would be doing them a disservice to exclude them from a surveillance programme.^{8,9} Left sided colitis also carries an intermediate risk for colorectal cancer and as such our guidelines reflects this. Indeed, one of the signatories to the Forbes *et al* letter has himself advocated a similar approach after discussion with the patient.⁴

The guidelines were formulated on the best evidence available at present. Surveillance was being conducted in an extremely disorganised fashion in the UK, which is not acceptable in the current climate of clinical governance. The BSG has properly encouraged a national approach to cancer surveillance in a range of colonic diseases. The principles, which underlie such an approach, are that of best practice throughout the country. The law no longer relies on the Bolam principle; rather

we are now expected to practice to the best standards.¹ If we are to offer long term care to patients with inflammatory bowel disease we must discuss with them the nature of surveillance and its inadequacies. If patients then choose to have surveillance we are obligated to provide a service which reaches the highest standards—standards similar to those in other screening services.

J A Eaden, J F Mayberry

Department of Gastroenterology, Walsgrave Hospital, Clifford Bridge Road, Coventry CV2 2DX, UK

Correspondence to: J F Mayberry; jmaybe@tiscali.co.uk

References

- 1 *Wilsher v Essex Area Health Authority*. (1986) 3 All ER 801.
- 2 *Early v Newham Health Authority*. (1984) 5 Med LR 214.
- 3 **Eaden JA**, Mayberry MK, Scherr, *et al*. Screening: the legal view. *Public Health* 2001;**115**:218–21.
- 4 **Lennard-Jones JE**, Young GP, Rozen P, *et al*. Prevention and early detection of colorectal cancer. In: *Prevention of Cancer in Inflammatory Bowel Disease*. London: WB Saunders, 1996:217–38.
- 5 **Lynch DAF**, Lobo AJ, Sobala GM, *et al*. Failure of colonoscopic surveillance in ulcerative colitis. *Gut* 1993;**34**:1075–80.
- 6 **Eaden JA**, Ward B, Mayberry JF. How British gastroenterologists screen for colonic cancer in ulcerative colitis: An analysis of performance. *Gastrointest Endosc* 2000;**52**:153–8.
- 7 **Eaden JA**, Abrams K, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;**48**:526–35.
- 8 **Gillen CD**, Andrews HA, Prior P, *et al*. Crohn's disease and colorectal cancer. *Gut* 1994;**35**:651–5.
- 9 **Gyde SN**, Prior P, Allan RN, *et al*. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. *Gut* 1988;**29**:206–17.

Crohn's disease: ethnic variation in CARD15 genotypes

Crohn's disease shows significant variability in incidence between different world populations. For example, Kurata and colleagues¹ studied the annual incidence of Crohn's disease in Caucasian, African, Asian, and Hispanic individuals, with an observed range from 43.6 per 100 000 population for Caucasian, 29.8 for African, 5.6 for Asian, and 4.1 for Hispanics. Recently, a genetic basis for Crohn's disease has been described.² The CARD15 gene (NOD2; MIM 605956) acts as a sensor for bacterial products. When functioning correctly, this would lead to activation of nuclear factor κ B.³ Sixty seven variations in the CARD15 genomic sequence have been reported.^{4,5} Of these 67, three variations (2104 C>T [R702W]; 2722 G>C [G908R]; 3020ins [1007fs]) have been consistently correlated with increased susceptibility to Crohn's disease.^{4,6–8}

Currently, these three variants have only been extensively assessed in patients of European, French Canadian, or American Caucasian descent. Using Pyrosequencing, we analysed all three variants in genomic DNA from 95 European (American Caucasian), 95 African (Ghanaian), and 53 Asian (Chinese) unrelated healthy volunteers. Frequencies for the R702W variant allele were 2% and 0% in European and African samples, respectively,

3% and 1% for G908R, and 3% and 0% for 1007fs ($p < 0.05$ in all cases). None of the variants was observed in the Asian population, consistent with a recent study of Japanese patients with Crohn's disease.⁹ The ethnic variation seen here could, in part, contribute to the variations in the frequency of Crohn's disease in different world populations. Attention should be paid to the discovery of novel geographically selective variants before evaluating association with Crohn's disease in non-European populations.

S Marsh, H L McLeod

Department of Medicine, Washington University School of Medicine, the Siteman Cancer Center, and the CREATE Pharmacogenetic Research Network, St Louis, MO, USA

Correspondence to: H L McLeod, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, St Louis, MO 63110-1093 USA; hmcleod@im.wustl.edu

Acknowledgements

This work was supported in part by UO1 GM63340.

References

- 1 **Kurata JH**, Kantor-Fish S, Frankl H, *et al*. Crohn's disease among ethnic groups in a large health maintenance organization. *Gastroenterology* 1992;**102**:1940–8.
- 2 **McGovern DPB**, van Heel DA, Ahmad T, *et al*. NOD2 (CARD15), the first susceptibility gene for Crohn's disease. *Gut* 2001;**49**:752–4.
- 3 **Ogura Y**, Inohara N, Benito A, *et al*. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF- κ B. *J Biol Chem* 2001;**276**:4812–18.
- 4 **Hugot J-P**, Chamaillard M, Zouali H, *et al*. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001;**411**:599–603.
- 5 **Vermeire S**, Wild G, Kocher K, *et al*. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship and haplotype structure. *Am J Hum Genet* 2002;**71**:74–83.
- 6 **Ogura Y**, Bonen DK, Inohara N, *et al*. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001;**411**:603–6.
- 7 **Hampe J**, Cuthbert A, Croucher PJP, *et al*. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. *Lancet* 2001;**357**:1925–8.
- 8 **Lesage S**, Zouali H, Cézard J-P, *et al*. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. *Am J Hum Genet* 2002;**70**:845–57.
- 9 **Inoue N**, Tamura K, Kinouchi Y, *et al*. Lack of common NOD2 variants in Japanese patients with Crohn's disease. *Gastroenterology* 2002;**123**:86–91.

Doctor or technician

In 1984, Sir Christopher Booth (President British Society of Gastroenterology (BSG) 1979) gave a lecture in Berlin on the effect of technology on clinical practice. He lauded the rapidly expanding benefits of diagnostic and interventional gastrointestinal endoscopy but was led to ask "Will the gastroenterologist simply become a technician who carries out a series of complex but personally satisfying techniques?"¹

Most gastroenterologists remain general physicians but in talking with specialist

registrars I have been surprised by their overwhelming interest in honing endoscopic skills. If this leads to a simplistic approach to the investigation of possible gastrointestinal pathology, it has its dangers. Analysis of two cases in the past month reminded me of this.

Case No 1

An elderly man was admitted to hospital with severe anaemia. The houseman obtained a history of aspirin ingestion and, over the preceding few weeks, recurrent melaena. He described feeling a hard liver edge. A blood count showed haemoglobin (Hb) 4.3, mean corpuscular volume (MCV) 55.7, white blood cell count (WCC) 6.6, and platelets 63. The patient was transfused and without further investigation the physician/gastroenterologist arranged for oesophago-gastro-duodenoscopy (OGD) and colonoscopy.

At OGD the stomach was described as showing a moderate erythematous/exudative gastritis. At colonoscopy no abnormality was seen apart from a little fresh bleeding, the cause of which was not apparent. The patient was allowed to go home only to be admitted 36 hours later with faecal peritonitis. The colon had been perforated at the rectosigmoid junction. The patient recovered well from reparative surgery but died six weeks later of multiorgan failure. At necropsy he was found to have cirrhosis of the liver. In retrospect, photographs of the gastric mucosa were consistent with portal gastropathy.

Case No 2

An elderly man taking diclofenac for osteoarthritis of the hip began drinking heavily after the death of his wife. One Saturday he felt faint, vomited black fluid, and passed melaena. After the weekend he was admitted to hospital. His blood count showed Hb 9.7, MCV 105, WCC 10.3, and platelets 240. As in case No 1, he was listed for OGD and colonoscopy. At OGD he was found to have a marked antral gastritis and multiple duodenal erosions in a deformed duodenal cap. At colonoscopy, multiple diverticulae were found in the sigmoid colon through one of which instrumental perforation occurred. The patient was referred promptly for surgery. There was little faecal contamination and the patient recovered well after resection of a short length of colon.

In both of these cases the physician-gastroenterologists appeared to be working to the dictum: bleeding from the gut requires OGD and colonoscopy. Yet in neither case was the need for colonoscopy clearly indicated. So was Chris Booth right to be concerned about what technology has done to gastroenterology? Or is it just fortuitous that I should be asked about these two cases so close to one another?

In the USA, many health care organisations suggest that this sort of issue should be addressed by paying more attention to the balance between underuse, overuse, and misuse of medical interventions.² So perhaps the programmes for meetings of the BSG should not be just sectionalised by organ and disease processes. A section devoted to efficiency, care, and safety in gastroenterological practice could gather together contributions having a direct and immediate bearing on clinical care. For as Sir Cyril Chantler said, when addressing the Institute of Health Services Research in the USA, "Medicine used to be simple, ineffective and relatively safe. Now it is complex, effective and

potentially dangerous".³ And we should all remain aware of this.

G Neale

Clinical Skills Centre, University College, Rockefeller Building, 21 University St, London WC1E 6JJ, UK; g.neale@ucl.ac.uk

References

- 1 Booth CC. What has technology done to gastroenterology? *Gut* 1985;**26**:1088-94.
- 2 Lee TH. A broader concept of medical errors. *N Engl J Med* 2002;**347**:1965-6.
- 3 Chantler C. The role and education of doctors in the delivery of healthcare. Hollister Lecture delivered at the Institute of Health Services Research, Northwestern University, Illinois, USA. October 1998. *Lancet* 1999;**353**:1178-81.

Which 5-ASA?

I read Dr Travis' therapy update (*Gut* 2002;**51**:548-9) with interest; the topic is timely in a market about to be challenged by new generic mesalazine brands. I note the choice of time dependent mesalazine (Pentasa) but, if mesalazine is to be relied upon exclusively, some evidence suggests Pentasa may not be the best choice. The recent study by Kruis and colleagues¹ in the maintenance of remission in ulcerative colitis (UC) found that with Pentasa 1.5 g/day, the six month remission rate was 56.8% compared with 77.5% with balsalazide 3 g twice daily (p=0.045).

The assertion that the advantages of the azo bond delivery to the distal colon can be matched by simply increasing the dose of pH dependent (Asacol) or time dependent release (Pentasa) has not been borne out by laboratory or clinical studies. Tissue level studies have indicated that double dose mesalazine is delivered to the kidney, not the colon.² A large clinical trial of Pentasa in mild to moderate active UC found remission rates of 29% for both 2 g/day and 4 g/day.³ This latter study highlights the lack of efficacy of mesalazine released by a time dependent delivery system in active UC. In contrast, three studies comparing balsalazide with mesalazine (pH dependent release),⁴⁻⁶ containing a total of 426 patients, all found balsalazide to be superior in active UC, with rapid resolution of symptoms (median 10 days in one study⁴) and superior sigmoidoscopic scores (in all three studies). Plasma concentrations of 5-aminosalicylic acid (5-ASA) were 4.5-fold lower in patients treated with balsalazide than mesalazine (p=0.018).⁵ Patients with most to benefit are new patients with distal disease.⁶ The use of 5-ASA in the initial treatment of UC does not require mega doses, as Dr Travis suggests, indeed mega doses of mesalazine delivered by Asacol or Pentasa are ineffective, but it does require a reliable delivery system, such as the azo bond, and an inert carrier, as with balsalazide. The clinical implication of this efficacy in mild to moderate active UC is that the threshold for the use of steroids can be raised. Of interest in the North American trials of balsalazide versus mesalazine, 60 patients failing mesalazine therapy were treated after the trial with balsalazide open label, with 60% response (data on file, Shire Pharmaceuticals Ltd).

Advocates of sulphasalazine (SASP) and those wishing to use the least expensive treatment cite trials of SASP versus newer agents⁷ and conclude that SASP is the most cost

effective; these trials are in patients with known UC and specifically exclude patients who are SASP intolerant. In two recently published studies,^{8,9} patients with newly diagnosed or previously untreated UC were randomised to SASP or balsalazide; 34% were intolerant of SASP at the modest dose of 3 g daily compared with 5% for balsalazide 6.75 g daily. The number needed to treat to avoid SASP intolerance at this rate is only 3, and in new patients it seems particularly important to use well tolerated effective treatment first-line and avoid the loss of confidence that drug intolerance produces.

It seems a sad reflection on the pharmaceutical industry sponsored research that the most recent trial on UC treatment with 5-ASA quoted in the therapy update was from 1998. Large clinical trials of one 5-ASA brand against another are expensive and the advent of generic mesalazine preparations is unlikely to improve this situation. My interpretation of recently published evidence is that the mesalazine release mechanism is important for the efficacy, reliability of delivery, and safety of the oral preparations and that balsalazide is now the gold standard for other agents to be judged against.

J C Mansfield

Royal Victoria Infirmary, Newcastle NE1 4LP, UK; john.mansfield@nuth.northy.nhs.uk

Conflict of interest: The author has accepted hospitality from the manufacturers of all of the current 5-ASA preparations, and sat on an advisory panel for Shire.

References

- 1 Kruis W, Schreiber S, Thuermer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3 g twice daily) was superior in preventing relapses. *Gut* 2001;**49**:783-9.
- 2 Hussain FN, Ajjan RA, Riley SA. Dose loading with delayed release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. *Br J Clin Pharmacol* 2000;**49**:323-30.
- 3 Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. *Am J Gastroenterol* 1993;**88**:1188-97.
- 4 Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. *Gastroenterology* 1998;**114**:15-22.
- 5 Levine DS, Riff DS, Pruitt R, et al. A randomized double blind dose response comparison of balsalazide 6.75g, balsalazide 2.25g and mesalamine 2.4g in the treatment of active mild-to-moderate ulcerative colitis. *Am J Gastroenterol* 2002;**97**:1398-407.
- 6 Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. *Am J Gastroenterol* 2000;**97**:3078-86.
- 7 Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis (Cochrane review). *Cochrane Library*, issue 4. Oxford: Update Software, 2000.
- 8 Green JRB, Mansfield JC, Gibson JA, et al. A double blind comparison of balsalazide 6.75g daily and sulfasalazine 3g daily in patients with newly diagnosed or recently relapsed active ulcerative colitis. *Aliment Pharmacol Ther* 2002;**16**:61-8.
- 9 Mansfield JC, Gaffer MH, Cann PA, et al. A double blind comparison of balsalazide 6.75g and sulfasalazine 3g as sole therapy in the management of ulcerative colitis. *Aliment Pharmacol Ther* 2002;**16**:69-77.

TIPS for gastric varices

We recently read with interest the study by Tripathi and colleagues¹ investigating the outcome of TIPS in patients with gastric (GV) compared to oesophageal varices (OV). This study confirmed the previous finding of lower mean portosystemic pressure gradient (PPG) in patients with GV bleeding relative to those with a history of OV bleeding.² Indeed in this study 35% (14/40) of GV patients compared to only 8% (20/2320) of OV patients had a PPG <12 mm Hg.

The group of patients who bleed at PPG <12 mm Hg (group 1) is particularly intriguing. As mentioned by the authors, low PPG in GV patients has been shown to correlate with the presence and size of a spontaneous gastrorenal shunt (GRS) which is present in up to 85% of GV patients but present in only about 20% of OV patients.³ Previously, Sanyal *et al* found that 50% (6/12) of patients who underwent TIPS for prevention of GV re-bleeding failed to decompress the varices as documented by endoscopy. 4/6 of these patients had a large GRS and a PPG <12 mm Hg. Thus based on probability, the group 1 patients in the current study (both GV and OV) are likely to have had a spontaneous GRS already decompressing the portal system. It would be valuable to know if the authors have any data on the presence of GRS in their patient population, perhaps documented by portogram taken at the time of TIPS? Also, did they document decompression of varices post-TIPS as an indicator of the clinical efficacy of the procedure? For example, it would be interesting to know if patients in group 1 failed to decompress varices post-TIPS more often than patients in group 2. Anecdotally, we have experience of a number of patients with large GV who had a baseline PPG of <12 mm Hg and a large GRS. Following TIPS in these patients, there was a minimal or no reduction in PPG and filling of the GV was not shown to be reduced on post-TIPS portogram.

Finally the authors noted in group 2 (baseline PPG >12 mm Hg) that lower post-TIPS PPG was associated with a lower risk of bleeding, as would be hoped. However in group 1, there was no difference in post-TIPS PPG between patients who did and did not re-bleed, suggesting that PPG may not be a critical determinant of variceal bleeding in patients who have a low PPG to start with. The role of PPG in dictating the natural history of GV is not known. Conceptually, insertion of an artificial portosystemic shunt into a patient who already has a large spontaneous shunt effectively offloading the portal pressure would not seem to confer much benefit. Do these GV (and possibly OV) patients with low PPG pre-TIPS and with a possible GRS really benefit from TIPS?

MR angiography can accurately assess for presence of a spontaneous GRS.⁴ There is a compelling argument that this should be an essential part of the assessment algorithm of patients with GV. If a large spontaneous shunt is present, and PPG (as measured by hepatic vein wedge pressure gradient (HVPG)) is <12 mm Hg, then perhaps other therapeutic options such as B-RTO (balloon occluded-retrograde transvenous obliteration) should be considered.

Hopefully more prospective data, examining the role of PPG, TIPS, and B-RTO in the

management and outcome of GV will help clarify these issues.

B M Ryan, R W Stockbrugger

University Hospital Maastricht, Maastricht, The Netherlands

J M Ryan

Division of Interventional Radiology, Duke University Medical Centre, Durham, North Carolina

Correspondence to Dr Ryan, Department of Gastroenterology, University Hospital Maastricht, Postbus 5800, 6202 AZ Maastricht, The Netherlands; bbryan@planet.nl

References

- 1 **Tripathi D**, Therapondos G, Jackson E, *et al*. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. *Gut* 2002;**51**:270–4.
- 2 **D'Amico G**, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. *Hepatology* 1995;**22**:332–54.
- 3 **Watanabe K**, Kimura K, Matsutani S, *et al*. Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. *Gastroenterology* 1988;**95**:434–40.
- 4 **Ono N**, Toyonaga A, Nishimura H, *et al*. Evaluation of magnetic resonance angiography on portosystemic collaterals in cirrhotic patients. *Am J Gastroenterol* 1997;**92**:1515–9.

Authors' reply

We agree that the presence of gastrorenal shunts (GRS) is likely to explain the low portal pressure gradient (PPG) post-transjugular intrahepatic portosystemic stent shunt (TIPS). Portography at the time of index TIPS insertion was primarily performed to identify varices and not specifically to look for the presence of GRS, although the splenic vein was visualised if not always in its entirety. Given these limitations, we have looked at the portograms of over 400 patients who have had a TIPS for any cause, and identified shunts in 18.3%. A wider portographic review and a prospective magnetic resonance angiography study will be required to answer the questions raised. For the study period, we used a post-TIPS PPG <12 mm Hg as an indicator of the efficacy of the TIPS procedure for patients with both gastric and oesophageal variceal bleeding. In light of our findings we have revised our target PPG post-TIPS to <7 mm Hg.

Our finding of a lack of a statistical difference in the post-TIPS PPG of those patients who did or did not rebleed may be due to the small numbers in group 1. It may be that factors other than portal pressure such as variceal size and variceal wall tension¹ play an important part in the risk of variceal bleeding in patients with a PPG of <12 mm Hg. It is also true that portal pressure directly affects the variceal wall tension, and attempts to reduce the portal pressure by a TIPS will be beneficial. We strongly believe that TIPS has a significant role in patients who have refractory gastric variceal bleeding, as mirrored by studies from others.² At the present time it is the most effective non-surgical method of treating gastric variceal haemorrhage and preventing rebleeding. Other therapeutic options are promising, and we have previously reported on the effective use of human thrombin in the treatment of acute gastric

variceal haemorrhage.³ However, controlled studies are required before universal recommendation of endoscopic therapies for gastric variceal haemorrhage.

D Tripathi, G Therapondos, P C Hayes

Centre for Liver and Digestive Disorders and Department of Medicine, the Royal Infirmary, Edinburgh, UK

D N Redhead

Department of Radiology, the Royal Infirmary, Edinburgh, UK

Correspondence to: D Tripathi, Department of Medicine, Royal Infirmary of Edinburgh, 1 Lauriston Place, Edinburgh EH3 9YW, UK; d.tripathi@ed.ac.uk

References

- 1 **Polio J**, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. *Semin Liver Dis* 1986;**6**:318–31.
- 2 **Chau TN**, Patch D, Chan YW, *et al*. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. *Gastroenterology* 1998;**114**:981–7.
- 3 **Yang WL**, Tripathi D, Therapondos G, *et al*. Endoscopic use of human thrombin in bleeding gastric varices. *Am J Gastroenterol* 2002;**97**:1381–5.

BOOK REVIEWS



ABC of Liver, Pancreas and Gall Bladder

Edited by I Beckingham. London: BMJ Publishing Group, 2001, £16.95, pp 54. ISBN 0-7279-1531-2

The *ABC Series* are well established as handy reference guides but they sometimes struggle from not being clear about their target readership. Midway between a textbook and an update, this publication follows the usual format. The topic is covered from investigations used in liver and biliary disease to the clinical conditions themselves, ranging from gall stones to liver and pancreatic transplantation. Because of the nature of the clinical area, the book will probably appeal more to the hospital clinician than the general practitioner although the latter will gain much in having a source of reference for unusual and awkward clinical situations.

Although the list of topics is complete, there are still problems in interpreting some of the information for use in the pragmatic clinical setting. The section on gall stones, for example, while full with detail of aetiology and presentation does not make it any easier for the clinician trying to decide whether to refer the patient with stones or when cholecystectomy is indicated. It may well be that in some areas, such as gall stone management, clinical judgement still outdistances evidence but it would have been useful to have had

available evidence about different management approaches.

The book also has a feel of having been constructed from an upstream viewpoint. Apart from a hepatologist, the other five contributors are all surgeons—it might have been useful to have had the perspectives of a general physician and a general practitioner, even if only to raise the pragmatic queries that arise at the earlier stage of management of hepatobiliary problems. An example is the potential prophylactic management of patients with varices. As it stands, variceal management in this publication commences essentially after the bleed with only a few lines on prophylactic management, and even those largely dismissive of possible measures apart from the global use of beta blockers. So what should a primary care practitioner dealing with a patient who might have varices actually do, and at what stage of abnormal liver tests or clinical findings is referral likely to be rewarding?

Increasingly, on a worldwide basis, a primary care clinician or a general practitioner with generic interests provides initial health-care. Many of them will rely on such publications as a ready source of information. Ease of access to the information is important—this is assisted in this *ABC* by the use of summary points and clear illustrations. The aim of the publication is given as the desire to provide an overview and to enable the clinician to keep abreast of advances in the common and the rarer conditions. It succeeds in this.

P Hungin

Therapeutic Roles of Selective COX-2 Inhibitors

Edited by J R Vane, R M Botting. William Harvey Press, 2001. ISBN-0 9534039-1-2

The review editor sent me a book to review for *Gut* with holidays looming. He left a week before me and is currently observing whales off the east coast of the USA where I hope he will encounter the albino whale. I, on the other hand, am in a more peaceful location surrounded by the truly magnificent lochs, standing stones, stone circles, chambered cairns, duns, and crannogs on the Outer Hebridean island of North Uist.

The book *Therapeutic Roles of Selective COX-2 Inhibitors* is the latest in a series of similar books edited by Vane and Botting, and I have found it in many ways as interesting and extraordinary as my surroundings. It exceeded all expectations, bringing together some of the people that have driven the COX-2 story through from birth of a concept to a marketable drug.

Vane and Botting set the pace with an authoritative introduction, elegantly outlining the history, biochemistry, and physiology of COX inhibition and its clinical potential. In this book they gracefully allow etodolac and nimesulide into the privileged COX-2 selective club or, as they call it, the "COX-1 sparing drug" club. Then follow high quality chapters on the discovery and studies on rofecoxib and celecoxib along with discussions on the various test systems to assess selectivity. The excitement of reading Derek Willoughby's chapter on COX-2 in inflammation in experimental models kept me awake for the whole night. This is a true master at work!

At last (Ballou *et al*) a detailed and intelligent account of the lessons that we should have learned from the study of COX-1 and -2 deficient animals. Indeed the knee jerk response, if not silence, to "unexpected" data obtained from these animals, such as the lack of gastrointestinal damage in COX-1 knock-outs, simply allows prevailing simplistic theories on the role of the two enzymes to be maintained a bit longer. The following chapters on enzymes in nociception, Alzheimer's disease, kidney, apoptosis, labour, cardiovascular system, arthritis, and bone are a treat, and reflect the scope of the book. Whittle, Hawkey, and Roderiguez could have combined their three chapters on the gastrointestinal toxicity of NSAIDs as their knowledge is complementary. They invade each others "intellectual" territory which gives the impression of conflict and confusion where none exists. The chapter by DuBois on COX-2 in colorectal cancer is only disappointing because of its brevity; the man has so much more knowledge to share! However, this is partially compensated by an excellent review of the role of COX-2 in other cancers. The book ends with rather biased accounts on the virtues of each of the COX-2 selective agents.

This book is currently the best available reference source on a subject that is growing in importance and complexity. The only irritations are some unnecessary self congratulatory comments and unashamed pleas for financial support that will raise the eyebrows of the purchaser of this book in Hay-on-Wye bookshops at the end of this century. I can thoroughly recommend it for all established prostaglandin and COX researchers, and PhD students. Clinical gastroenterologists will find something new of interest. Those with time, concentration, and a biochemical background will surely enjoy this book as much as I did.

Aah! Catherine my lifelong companion has just brought me a wee dram (Talisker single malt whisky with 10% v/v local water). Life just does not get much better than this. My euphoria is however marred by the knowledge that the COX-2 selective drugs are not available to the citizens of Cuba as a result of the USA's embargo.

I Bjarnason

Drug-Induced Liver Disease

Edited by N Kaplowitz, L D DeLeve. New York: Marcel Decker, 2003, £195.00, pp 773. ISBN 0-8247-0811-3

On the face of it, this hardback does not sound like a very good bedtime read and splashing out £195 might seem a little extravagant for what might appear to be some dry tome that would readily gather dust on a shelf. It was therefore with some trepidation that I received this ostensibly uninviting 773 page beige and green covered book, and turning the pages quickly, the casual reader might still be deceived into casting it into the nether regions of a desk drawer or the dimmer corners of an office. However, I am pleased to say that these were all poorly grounded misapprehensions, because this is an expertly written and very neatly edited book by a whole galaxy of experts, covering the mechanisms of drug induced liver injury in an easily readable format (who cannot stand up and say that

paracetamol/acetaminophen poisoning is a mystery to most mere mortals, despite the fact we all know the antidote?). The book also contains a comprehensive set of chapters on the hepatotoxicity of specific drugs for quick and easy reference, which is set firmly in clinical context, and for the generalist, a very useful clinical section on diagnosis and management of drug induced liver disease.

Another reason not to look at such a book might be that many of those emanating from the USA have an American perspective only, but this is a real exception as at least one third of the chapters are written by authors from countries as far apart as Switzerland and India and the book as a whole develops a truly international theme. It is well referenced in a very authoritative and up to date way, and sheds light on a whole host of topics that are bothersome to most gastroenterologists, such as the usage of methotrexate in psoriasis and rheumatoid arthritis (with helpful guidelines on when to offer baseline and follow up liver biopsy and to whom), antituberculous agents (and when to worry!), and in this day and age, sections on psychotropic agents, drugs of abuse, and importantly, when many patients are keen to seek out the veritable pharmacopoeia that can be found in the average health food shop or in Chinatown, an authoritative compendium on alternative medicines, vitamins, and natural hepatotoxins. With the increasing incidence of certain liver tumours, I found sections on the adverse effects of hormones (covering everything from adenomas, focal nodular hyperplasia, and frank malignancies to vascular abnormalities in the liver) and on environmental toxins very interesting and informative.

While it is true to say that at the price, most people would not want to rush out and buy a copy immediately, I would wholeheartedly recommend that every hospital library invests in a copy for use by gastroenterology trainees, trainees from other disciplines, and even the odd consultant gastroenterologist! The book would be very useful for hospital pharmacists, nurse practitioners, and also for medical students who need to reference the subject in more depth. However, on considered reflection, I think that most gastroenterology units should think carefully about buying a copy—with increasing drug usage by patients, illicit or otherwise, it is an exploding problem. The book provides an aide memoire for those that need it and it won't gather dust for long!

S D Taylor-Robinson

NOTICES

New In Vivo Imaging Modalities for Molecular Biology, Cell Biology and Physiology

This Jacques Monod conference will be held on 31 May–4 June 2003 in Roscoff, France. Further information: Bertrand Tavitian, INSERM M10103, Service Hospitalier Frédéric Joliot, CEA Direction des Sciences du Vivant, Direction de la Recherche Médicale, 4 place du Général Leclerc, 91401 Orsay Cedex, France. Tel: +33 169 867 779; fax: +33 169 867 739; email: tavitian@shfj.cea.fr

Prague Hepatology Meeting

To be held on 5–7 June 2003 in Prague, Czech Republic. Leading speakers from Europe and the USA will present new ideas and suggestions on pathophysiology, diagnostics, and therapy of liver diseases in ten programmes blocks. Further details: Ms Veronica Revicka. Tel: +420 241 445 759; fax: +420 241 445 806; email: veronika@congressprague.cz

Falk Symposia—New Findings on Pathogenesis and Progress in Management of IBD

Two symposia and a workshop will be held on 10–14 June 2003 in Berlin, Germany. Further details: Falk Foundation e.V., Congress Division, PO Box 6529, Leinenweberstr. 5, 79041 Freiburg/Br, Germany. Tel: +49 761 15 140; fax: +49 761 15 14 359; email: symposia@falkfoundation.de; website: www.falkfoundation.de

Gastroenterology and Endotherapy: XXIst European Workshop

This will be held on 16–18 June 2003 in Brussels, Belgium. Further details: Nancy Beauprez, Administrative Secretariat of the Workshop, Gastroenterology Department, Erasme Hospital, Route de Lennik 808, B-1070 Brussels, Belgium. Tel: +32 (0)2 555 49 00; fax: +32 (0)2 555 49 01; email: beauprez@ulb.ac.be

The Association of Coloproctology of Great Britain & Ireland

This annual meeting will be held on 7–10 July 2003 in Edinburgh, UK. Further details: Conference Secretariat, The ACGBI at the Royal College of Surgeons of England, 35–43 Lincoln's Inn Fields, London WC2A 3PE. Tel: +44 (0)20 7973 0307; fax: +44 (0)20 7430 9235; email: acpgbi@asgbi.org.uk; website: www.acpgbi.org.uk

European Helicobacter Study Group (EHSG)

This meeting, on Helicobacter infections and gastroduodenal pathology, will be held on 3–6 September 2003 in Stockholm, Sweden. Further details: Professor Torkel Wadstrom, President- EHSG, Lund University, Department of Infectious Diseases & Medical Microbiology, Division of Bacteriology, Solvegatan 23, SE-223 62 Lund, Sweden. Tel: +46 46 173 241; fax: +46 46 152 564; email: Torkel.Wadstrom@mmb.lu.se; website: www.helicobacter.org

Falk Symposium 135—Immunological Diseases of Liver and Gut

This symposium will be held on 12–13 September 2003 in Prague, Czech Republic. Further details - see Falk Symposia above

The European Society of Parenteral and Enteral Nutrition (ESPEN)

ESPEN will celebrate its silver anniversary at the time of the annual congress, which is to be held on 20–23 September 2003 in Cannes, France. Further details: www.espen.org

XII Falk Liver Week

The XII Falk Liver Week, in honour of Hans Popper's 100th birthday, will be held on 15–22 October 2003 in Freiburg, Germany. Further details - see Falk Symposia above.

European Course on Laparoscopic Endoscopy

This course will be held on 18–21 November 2003 in Brussels, Belgium. Further details: Secretary to Professor Cadière, Service de Chirurgie Digestive, Rue Haute 322, Brussels 1000, Belgium. Tel: +32 (0)2 648 07 60; fax: +32 (0)2 647 86 94; email: straeb.asmb@proximedia.be; website: www.straeb-asmb.com

Hong Kong-Shanghai International Liver Congress 2004

This conference will be held on 14–17 February 2004 in Hong Kong. The topic of the conference is "Liver Diseases in the Post-Genomic Era". Further details: Ms Kristie Leung, Room 102–105 School of General Nursing, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel: +852 2818 4300/8101 2442; fax: +852 2818 4030; email: kristieleung@hepa2004.org; website: www.hepa2004.org



What's in the next issue

Future content

See which articles have just been accepted for publication and preview the table of contents for the next issue a month before it is published

www.gutjnl.com